Apolipoprotein ε2 allele is associated with an anti-atherogenic lipoprotein profile in children:: The Columbia University BioMarkers Study

被引:21
作者
Isasi, CR
Shea, S
Deckelbaum, RJ
Couch, SC
Starc, TJ
Otvos, JD
Berglund, L
机构
[1] Columbia Univ, Dept Med, New York, NY USA
[2] Columbia Univ, Dept Pediat, New York, NY USA
[3] N Carolina State Univ, Dept Biochem, Raleigh, NC 27695 USA
关键词
apolipoprotein epsilon; children; cholesterol;
D O I
10.1542/peds.106.3.568
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective. We examined associations between allelic variation in the apo epsilon gene, which codes for apolipoprotein E, and plasma lipid levels in children. Materials and Methods. We analyzed genotype and fasting lipid levels, including lipid particle size by nuclear magnetic resonance spectroscopy, in 515 children from 297 families. Results. Children carrying the apo epsilon 2 allele (1 or 2 epsilon 2 alleles; n = 45) had higher mean high-density lipoprotein (HDL) cholesterol level (49.5 +/- 13.0 vs 42.4 +/- 8.9 mg/dL) and lower mean low-density lipoprotein (LDL) cholesterol level (82.2 +/- 48.6 vs 105.9 +/- 45.0 mg/dL) compared with apo epsilon 3/epsilon 3 children (n = 322). Mean HDL size was larger and mean level of the atheroprotective large HDL subpopulation was higher among apo e2 carriers compared with epsilon 3/epsilon 3 children (9.5 +/- 0.4 vs 9.3 +/- .4 nm, and 32.8 +/- 9.9 vs 27.6 +/- 8.2 mg/dL). In multivariate models adjusting for age, sex, ethnicity, family history, body mass index, and fasting triglyceride level, the apo epsilon 2 allele was independently predictive of higher levels of HDL cholesterol and the large HDL subpopulation and of lower level of LDL cholesterol. Conclusion. The apo epsilon 2 allele is associated with an anti-atherogenic lipid pattern in children.
引用
收藏
页码:568 / 575
页数:8
相关论文
共 79 条
[1]   Characterization of low-density lipoprotein subclasses in children [J].
Arisaka, O ;
Fujiwara, S ;
Yabuta, K ;
Mokuno, H ;
Mitugi, Y ;
Miyake, N .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (02) :146-148
[2]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
[3]   ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].
AUSTIN, MA ;
KING, MC ;
VRANIZAN, KM ;
KRAUSS, RM .
CIRCULATION, 1990, 82 (02) :495-506
[4]   HIGH-DENSITY AND LOW-DENSITY LIPOPROTEIN SUBFRACTIONS IN SURVIVORS OF MYOCARDIAL-INFARCTION AND IN CONTROL SUBJECTS [J].
BALLANTYNE, FC ;
CLARK, RS ;
SIMPSON, HS ;
BALLANTYNE, D .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1982, 31 (05) :433-437
[5]  
Berenson GS, 1980, CARDIOVASCULAR RISK
[6]  
Berglund L, 1999, AM J CLIN NUTR, V70, P992
[7]   Interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins - The EARS study [J].
Boer, JMA ;
Ehnholm, C ;
Menzel, HJ ;
Havekes, LM ;
Rosseneu, M ;
OReilly, DS ;
Tiret, L .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (09) :1675-1681
[8]   Mouse models of atherosclerosis [J].
Breslow, JL .
SCIENCE, 1996, 272 (5262) :685-688
[9]   TYPE-III HYPERLIPOPROTEINEMIA - DIAGNOSIS, MOLECULAR DEFECTS, PATHOLOGY, AND TREATMENT [J].
BREWER, HB ;
ZECH, LA ;
GREGG, RE ;
SCHWARTZ, D ;
SCHAEFER, EJ .
ANNALS OF INTERNAL MEDICINE, 1983, 98 (05) :623-640
[10]  
CUMMING AM, 1984, CLIN GENET, V25, P310